Mary Frances McMullin, MD of Belfast City Hospital, Belfast, UK discusses targeted therapy and immunotherapy for acute myeloid leukemia (AML) held at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Prof. McMullin explains that she was part of a discussion at BSH on targeted therapy and immunotherapy for AML. We are in the era of molecular medicine as our understanding of mutations underlying disease is improving and she explains that this may change the treatment of AML.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates